Decision making in adjuvant trials in breast cancer: The NCIC CTG MA.17 trial as an example

Breast Cancer Research and Treatment

Volumn 108, Issue 2, 2008, Pages 265-269

  Pater, Joseph ^a   Tu, Dongsheng ^a   Shepherd, Lois ^a   Ingle, James N ^b   Goss, Paul E ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b MAYO CLINIC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant hormone therapy; Breast cancer; Clinical trials; Data safety monitoring; Disease free survival

Indexed keywords

LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CALCULATION; CANCER ADJUVANT THERAPY; CRITERION VARIABLE; DECISION MAKING; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTROLLED CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NITRILES; PATIENT SELECTION; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME; TRIAZOLES;

EID: 39749108446     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9595-7     Document Type: Article

References (22)

1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2003) A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
2. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
3. Bryant J, Wolmark N (2003) Letrozole after tamoxifen for breast cancer-what is the price of success? N Engl J Med 349:1855-1857
4. Cannistra SA (2004) The ethics of early stopping rules: who is protecting whom? J Clin Oncol 22:1542-1545
5. Cuzick J, Howell A, Forbes J (2005) Early stopping of clinical trials. Breast Cancer Res7:181-183
6. Buchanan D, Miller FG (2005) Principles of early stopping of randomized trials for efficacy: a critique of equipoise and an alternative nonexploitation ethical framework. Kennedy Inst Ethics J 15:161-178
7. Partridge AH, Slutsman J, Hunsberger SA, Sledge G, Mayer M, Schilsky RL (2005) Ethical and clinical dilemmas resulting from the early closure of recent clinical trials in breast cancer. Am Soc Clin Oncol Educational Book 230-241
8. Goss PE, Ingle JN, Pater JL (2004) Correspondence. N Engl J Med 350:728-729
9. Pater JL, Goss P, Ingle J, Shelley W, Shepherd L (2005) The ethics of early stopping rules (Letters/correspondence). J Clin Oncol 23:2862
10. Girling D, Parmar M, Stenning S, Stephens R, Stewart L (2003) Clinical trials in cancer. Principles and practice. Oxford University Press, New York (NY), 245p
11. Fisher B, Dignam J, Wieand S, Wolmark N, Wickerham DL (1996) Duration of tamoxifen (TAM) therapy for primary breast cancer: 5 versus 10 years (NSABP-14). Proc Am Soc Clin Oncol 15:113
12. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15
13. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of randomized trials. Lancet 351:1451-1467
14. Girling D, Parmar M, Stenning S, Stephens R, Stewart L (2003) Clinical trials in cancer. Principles and practice. Oxford University Press, New York (NY), 229p
15. Wieand S (2003) Is relative risk reduction a useful measure for patients or families who must choose a method of treatment? J Clin Oncol 21:4263-4264
16. McAlister FA, Strauss SA, Guyatt GH, Haynes RB (2000) Users' guide to the medical literature. XX. Integrating research evidence with the care of the individual patient. JAMA 283:2829-2836
17. Girling D, Parmar M, Stenning S, Stephens R, Stewart L (2003) Clinical trials in cancer. Principles and practice. Oxford University Press, New York (NY), 105p
18. Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D (2005) Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Breast Cancer Res Treat 94(Supp1):S10-S11
19. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2006) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295-300
20. Harris SR (2004) Correspondence. N Engl J Med 350:728
21. Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411
22. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro AM, Hoy K et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the women's intervention nutrition study. J Nat Cancer Inst 98:1767-1776